PRAGUE, Czech Republic, June 24, 2011 /PRNewswire/ —
The randomised, double-blind, placebo-controlled multi-centre study (abstract no. 2511) investigated the efficacy and safety of the monoclonal antibody rituximab (RTX) in 197 ANCA-associated vasculitis (AAV) patients. This study showed that in patients with severe AAV a single course of rituximab for remission induction and maintenance over a period of 18 months proved to be as effective as standard therapy.
Another important research study. Rest of the article is here.
What I say: The patients with WG (AAV is another name for it) have known that Rituximab is very effective for patients who have been diagnosed early. Also, this treatment is not as hard on the patient and they can have a better quality of life.
The only downside (other than some minor side effects during treatment) is that it does uncover other auto-immune diseases that are not treatable by Rituximab. For instance, many WG patients find that they also have Crohn’s disease or other diseases, which this treatment does not help.
Baby steps – until we are all cured.